SCHEMBL18554121

SCHEMBL18554121

CCOC(=O)CCCCCOc1cc([N+](=O)[O-])c(C(=O)O)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TNF P01375 3/20 0.50
HTT P42858 1/20 0.46
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
MAPT P10636 1/20 0.42
NPC1 O15118 1/20 0.42
CYP3A4 P08684 1/20 0.42
PKM P14618 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4340073 0.91 TNF (0.50) TNFHTTPOLBL3MBTL1KDM4E
SCHEMBL643777 0.91 TNF (0.50) TNFHTTPOLBL3MBTL1KDM4E
SCHEMBL29620246 0.89 HTT (0.52) HTTPOLBL3MBTL1KDM4ELMNA
SCHEMBL2468068 0.89 HTT (0.52) HTTPOLBL3MBTL1KDM4ELMNA
SCHEMBL14331200 0.87 TNF (0.52) TNFHTTPOLBL3MBTL1KDM4E
SCHEMBL20631194 0.86 HTT (0.51) HTTPOLBLMNANPC1CYP3A4
SCHEMBL16067368 0.86 HTT (0.51) HTTPOLBL3MBTL1LMNACASP3
SCHEMBL12221992 0.85 HTT (0.47) HTTPOLBL3MBTL1KDM4ELMNA
SCHEMBL1742989 0.85 POLB (0.47) HTTPOLBL3MBTL1KDM4ELMNA
SCHEMBL32690852 0.85 HTT (0.50) TNFHTTPOLBKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583857-B2 Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2026-03-24 US disclosed
US-20250011317-A1 ANTI-PROLIFERATIVE AGENTS PHEON THERAPEUTICS LTD (GB) 2025-01-09 US disclosed
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2024-02-27 US disclosed
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2024-02-27 US disclosed
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2024-02-27 US disclosed
US-20240002379-A1 ASYMMETRIC CONJUGATE COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2024-01-04 US disclosed
EP-4086251-A1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY Femtogenix Limited (GB) 2022-11-09 EP disclosed
CN-114907345-A Piperidine-benzodiazepine compound having anti-proliferative activity 福姆通格尼克斯有限公司 2022-08-16 CN disclosed
EP-3337795-B1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY FEMTOGENIX LTD (GB) 2022-06-22 EP disclosed
US-20210206763-A1 Anti-Proliferative Agents PHEON THERAPEUTICS LTD (GB) 2021-07-08 US disclosed
US-20190144443-A1 ASYMMETRIC CONJUGATE COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2019-05-16 US disclosed
US-20190144443-A1 ASYMMETRIC CONJUGATE COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2019-05-16 US disclosed
EP-3455225-A1 ASYMMETRIC CONJUGATE COMPOUNDS Femtogenix Limited (GB) 2019-03-20 EP disclosed
US-20180339985-A1 PDD COMPOUNDS FEMTOGENIX LIMITED (GB) 2018-11-29 US disclosed
US-20180291021-A1 PDD COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2018-10-11 US disclosed
EP-3337795-A1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY Femtogenix Limited (GB) 2018-06-27 EP disclosed
WO-2017194960-A1 ASYMMETRIC CONJUGATE COMPOUNDS FEMTOGENIX LIMITED (GB) 2017-11-16 WO disclosed
WO-2017194960-A1 ASYMMETRIC CONJUGATE COMPOUNDS FEMTOGENIX LIMITED (GB) 2017-11-16 WO disclosed
WO-2017032983-A1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY FEMTOGENIX LIMITED (GB) 2017-03-02 WO disclosed
WO-2017032983-A1 PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY FEMTOGENIX LIMITED (GB) 2017-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210206763-A1 Anti-Proliferative Agents CCND2, BRD2, DRD2 TNF 2091/4885HTT 3499/4885POLB 127/4885
US-12583857-B2 Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines CNR1, MTNR1B, MTNR1A TNF 3062/4885HTT 3054/4885POLB 2395/4885
US-20250011317-A1 ANTI-PROLIFERATIVE AGENTS CCND2, BRD2, CCND3 TNF 1997/4885HTT 3670/4885POLB 104/4885
US-20240002379-A1 ASYMMETRIC CONJUGATE COMPOUNDS TUBA1C, MTX2, CCNO TNF 1985/4885HTT 3874/4885POLB 3290/4885
US-20180291021-A1 PDD COMPOUNDS DRD1, DRD3, DRD2 TNF 3150/4885HTT 2338/4885POLB 1536/4885
US-20190144443-A1 ASYMMETRIC CONJUGATE COMPOUNDS TUBA1C, MTX2, CCNO TNF 2002/4885HTT 3888/4885POLB 3350/4885
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines MKI67, CCND2, CCND1 TNF 3768/4885HTT 3377/4885POLB 231/4885
US-20180339985-A1 PDD COMPOUNDS DRD1, DRD3, DRD2 TNF 3066/4885HTT 2611/4885POLB 1301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.